The mainstay of treatment for metastatic prostate cancer is androgen deprivation, but unfortunately all patients eventually become resistant to this treatment, developing androgen-independent cancer, with a median time to death of ≈1 year. In addition, taxanebased chemotherapy has met with limited success and is usually associated with significant toxicity. Recent research has suggested that ra...

*Author for correspondence: [email protected] Cancer is one leading cause of mortality that is associated with genetic background or environmental toxin [1]. Multiple anti-cancer therapies have been developed and applied clinically such as surgery, chemotherapy, radiotherapy, therapeutic antibody, small molecule, Antibody-Drug Conjugate (ADC), cellular immunotherapy, chemoimmunotherapy, and radioimm...

Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have meas...

Monoclonal antibody therapy may provide new treatment options in the management of metastatic breast cancer by selectively targeting tumors and producing a therapeutic effect, by delivering radiation or other toxins directly to tumor cells, or by producing an intrinsic immune inflammatory response. The effect of 131I-labeled humanized anti-Lewis(y) monoclonal antibody 3S193 (hu3S193) was compar...